অনুরূপ উপাদানগুলি: Black Book - Multiple Myeloma: Patients, Penetration Price & Duration Offer Upside for Celgene Through 2015
- Celgene Corporation SWOT Analysis
- White Book - Celgene: An Abundance of Revlimid Opportunities in Myeloma, But Maintenance Is the Biggest Driver
- Black Book - Inco: Upsides from Cost Reductions, Commodity Price Rebounds, Volume Gains & Exploration
- Bernstein Black Book - Biosimilars: Quo Vadis - A Snapshot of the Biosimilar Industry Halfway Through Its Formation
- Clinical lymphoma & myeloma
- Clinical Lymphoma and Myeloma